Diagnostic, prognostic, and predictive biomarkers in gastric cancer: from conventional to novel biomarkers.
1/5 보강
Gastric cancer is a major health concern worldwide.
APA
Khalili-Tanha G, Khalili-Tanha N, et al. (2024). Diagnostic, prognostic, and predictive biomarkers in gastric cancer: from conventional to novel biomarkers.. Translational research : the journal of laboratory and clinical medicine, 274, 35-48. https://doi.org/10.1016/j.trsl.2024.09.001
MLA
Khalili-Tanha G, et al.. "Diagnostic, prognostic, and predictive biomarkers in gastric cancer: from conventional to novel biomarkers.." Translational research : the journal of laboratory and clinical medicine, vol. 274, 2024, pp. 35-48.
PMID
39260559 ↗
Abstract 한글 요약
Gastric cancer is a major health concern worldwide. The survival rate of Gastric cancer greatly depends on the stage at which it is diagnosed. Early diagnosis is critical for improving survival outcomes. To improve the chances of early diagnosis, regular screening tests, such as an upper endoscopy or barium swallow, are recommended for individuals at a higher risk due to factors like family history or a previous diagnosis of gastric conditions. Biomarkers can be detected and measured using non-invasive methods such as blood tests, urine tests, breath analysis, or imaging techniques. These non-invasive approaches offer many advantages, including convenience, safety, and cost-effectiveness, making them valuable tools for disease diagnosis, monitoring, and research. Biomarker-based tests have emerged as a useful tool for identifying gastric cancer early, monitoring treatment response, assessing the recurrence risk, and personalizing treatment plans. In this current review, we have explored both classical and novel biomarkers for gastric cancer. We have centralized their potential clinical application and discussed the challenges in Gastric cancer research.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.